Physician profile
Anna Comstock
NPI 1508407131
$3,643.84
in general payments reported to CMS, 2019-2025
39 companies · $741 in 2025
The $741 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $681 · 2022: $587 · 2023: $842 · 2024: $792 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,375.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,099.72 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $328.02 | 2024 | Qelbree |
| Novo Nordisk INC | $222.83 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.82 | 2021-2025 | Jardiance |
| Pfizer INC. | $155.09 | 2021-2025 | |
| Amgen INC. | $143.79 | 2021-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $127.33 | 2021-2024 | Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $121.11 | 2023-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $97.45 | 2021-2025 | |
| Lilly USA, LLC | $96.39 | 2021-2025 | Jardiance, Mounjaro |
| Vanda Pharmaceuticals INC. | $87.61 | 2022-2023 | Hetlioz, Fanapt |
| Merck Sharp & Dohme LLC | $87.28 | 2021-2023 | Steglujan, Steglatro, Belsomra |
| Astellas Pharma US INC | $83.60 | 2023-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.81 | 2022-2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $56.39 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Comstock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.